small bowel Crohn disease

Summary

small bowel Crohn disease (MONDO:0005539) is a disease and 3 clinical trials. Top therapeutic interventions include filgotinib. A subtype of Crohn disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	small bowel Crohn disease
Mondo ID	MONDO:0005539
EFO	EFO:0005629
UMLS	C0156146
MedGen	57617
Is cancer (heuristic)	no

Also known as: small bowel Crohn’s disease

Disease family

This is a subtype of Crohn disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › inflammatory bowel disease › Crohn disease › small bowel Crohn disease

Related subtypes (4): Crohn’s colitis, oral Crohn disease, perianal Crohn disease, Crohn disease of the esophagus

Subtypes (3): Crohn ileitis, gastroduodenal Crohn disease, Crohn jejunitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03046056	PHASE2	COMPLETED	Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn’s Disease (SBCD)
NCT03646708	Not specified	ACTIVE_NOT_RECRUITING	Response Assessment in SB CD
NCT01555437	Not specified	COMPLETED	Assessment of Capsule Endoscopy Scoring Index (CESI), Harvey-Bradshaw Index (HBI) and Biological Markers in Small Bowel Crohn’s Disease (SBCD)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FILGOTINIB	4	1